Understanding how nanoparticles can overcome biological barriers in medicine
Official title: Probing nano/bio interactions to understand and overcome biological barriers limiting nanomedicine
Funded at University of Delaware · NIH-11101263 · Data updated 2026-11-12
This study is looking at tiny particles that can help deliver medicine more effectively to treat diseases, making it easier for doctors to target the right cells and improve patient care.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Delaware NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project start | June 1, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $408,005 |
| NIH project number | 5R35GM149292-03 |
| Project ID | NIH-11101263 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with aggressive cancers, blood disorders, or maternal/fetal health conditions.
✕Less likely to help
Patients with conditions that do not involve the biological barriers targeted by this research may not benefit.
What this research studies
This research focuses on engineering nanoparticles with special properties to improve the treatment of various diseases. By studying how these nanoparticles interact with biological systems, the team aims to enhance their ability to deliver therapies directly to affected cells. The approach includes using nanoparticles to deliver antibodies or nucleic acids that can inhibit disease progression, as well as utilizing light to activate treatments specifically in diseased tissues. The research also explores how the design and packaging of these nanoparticles influence their effectiveness in overcoming biological barriers.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted treatments for aggressive cancers and blood disorders.
How similar studies have gone: Previous research has shown promise in using nanoparticles for targeted drug delivery, indicating potential success for this approach.
Where this research is happening
-
University of Delaware
Newark, United States Active
Researchers
- Principal investigator: Day, Emily S — University of Delaware
- Study coordinator: Day, Emily S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.